Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
A Report of the AAN Guidelines Subcommittee
This article has a related notice.
VIEW NOTICEThis guideline is retired. The recommendations and conclusions are no longer considered valid and no longer supported by the AAN. Retired guidelines should be used for historical reference only. Please see AAN current guidelines here.
Information & Authors
Information
Published In
Copyright
© 2022 American Academy of Neurology.
Publication History
Received: October 27, 2021
Accepted: January 25, 2022
Published online: February 23, 2022
Published in issue: April 12, 2022
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Retirement of Guidelines, Neurology, 104, 9, (2025)./doi/10.1212/WNL.0000000000213572
- Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation, Neurotherapeutics, 22, 3, (e00548), (2025).https://doi.org/10.1016/j.neurot.2025.e00548
- A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system, Frontiers in Pharmacology, 16, (2025).https://doi.org/10.3389/fphar.2025.1522058
- Innovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease, PLOS Biology, 23, 2, (e3003046), (2025).https://doi.org/10.1371/journal.pbio.3003046
- Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer’s Disease, Molecular Neurobiology, (2025).https://doi.org/10.1007/s12035-024-04484-y
- 11C-Labeling of a Flavanone Extracted from a South American Native Species for Evaluation of Its Interaction with GSK-3β, Molecules, 30, 4, (874), (2025).https://doi.org/10.3390/molecules30040874
- Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates, Disease-a-Month, (101863), (2025).https://doi.org/10.1016/j.disamonth.2025.101863
- Testing cognitive normal for Alzheimer's disease prediction, Journal of Neurochemistry, 169, 1, (2024).https://doi.org/10.1111/jnc.16272
- Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer’s Disease, International Journal of Molecular Sciences, 25, 22, (12029), (2024).https://doi.org/10.3390/ijms252212029
- Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review, Exploration of Neuroprotective Therapy, (411-441), (2024).https://doi.org/10.37349/ent.2024.00092
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.